266 related articles for article (PubMed ID: 21079151)
1. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.
Sørensen RB; Hadrup SR; Svane IM; Hjortsø MC; Thor Straten P; Andersen MH
Blood; 2011 Feb; 117(7):2200-10. PubMed ID: 21079151
[TBL] [Abstract][Full Text] [Related]
2. The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.
Andersen MH
Cancer Immunol Immunother; 2012 Aug; 61(8):1289-97. PubMed ID: 22388712
[TBL] [Abstract][Full Text] [Related]
3. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.
Munir S; Larsen SK; Iversen TZ; Donia M; Klausen TW; Svane IM; Straten PT; Andersen MH
PLoS One; 2012; 7(4):e34568. PubMed ID: 22539948
[TBL] [Abstract][Full Text] [Related]
4. Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase.
Rytelewski M; Meilleur CE; Yekta MA; Szabo PA; Garg N; Schell TD; Jevnikar AM; Sharif S; Singh B; Haeryfar SM
PLoS One; 2014; 9(2):e90439. PubMed ID: 24587363
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.
Sørensen RB; Køllgaard T; Andersen RS; van den Berg JH; Svane IM; Straten Pt; Andersen MH
Cancer Res; 2011 Mar; 71(6):2038-44. PubMed ID: 21406395
[TBL] [Abstract][Full Text] [Related]
6. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.
Sørensen RB; Berge-Hansen L; Junker N; Hansen CA; Hadrup SR; Schumacher TN; Svane IM; Becker JC; thor Straten P; Andersen MH
PLoS One; 2009 Sep; 4(9):e6910. PubMed ID: 19738905
[TBL] [Abstract][Full Text] [Related]
7. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression.
Liu H; Liu L; Liu K; Bizargity P; Hancock WW; Visner GA
J Immunol; 2009 Jul; 183(2):1022-31. PubMed ID: 19564344
[TBL] [Abstract][Full Text] [Related]
8. IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells.
Curran TA; Jalili RB; Farrokhi A; Ghahary A
Immunobiology; 2014 Jan; 219(1):17-24. PubMed ID: 23891282
[TBL] [Abstract][Full Text] [Related]
9. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.
Noh KT; Son KH; Jung ID; Kang TH; Choi CH; Park YM
J Biol Chem; 2015 May; 290(19):12394-402. PubMed ID: 25814664
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells.
Jürgens B; Hainz U; Fuchs D; Felzmann T; Heitger A
Blood; 2009 Oct; 114(15):3235-43. PubMed ID: 19625705
[TBL] [Abstract][Full Text] [Related]
11. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity.
Gu T; Rowswell-Turner RB; Kilinc MO; Egilmez NK
Cancer Res; 2010 Jan; 70(1):129-38. PubMed ID: 20028855
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase, Tregs and cancer.
Munn DH
Curr Med Chem; 2011; 18(15):2240-6. PubMed ID: 21517755
[TBL] [Abstract][Full Text] [Related]
13. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.
Baban B; Chandler PR; Sharma MD; Pihkala J; Koni PA; Munn DH; Mellor AL
J Immunol; 2009 Aug; 183(4):2475-83. PubMed ID: 19635913
[TBL] [Abstract][Full Text] [Related]
14. Allostimulatory activity of bone marrow-derived plasmacytoid dendritic cells is independent of indoleamine dioxygenase but regulated by inducible costimulator ligand expression.
Colvin BL; Sumpter TL; Tokita D; Salati J; Mellor AL; Thomson AW
Hum Immunol; 2009 May; 70(5):313-20. PubMed ID: 19208362
[TBL] [Abstract][Full Text] [Related]
15. The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
Shibata Y; Hara T; Nagano J; Nakamura N; Ohno T; Ninomiya S; Ito H; Tanaka T; Saito K; Seishima M; Shimizu M; Moriwaki H; Tsurumi H
PLoS One; 2016; 11(1):e0146279. PubMed ID: 26727596
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.
Sharma MD; Hou DY; Liu Y; Koni PA; Metz R; Chandler P; Mellor AL; He Y; Munn DH
Blood; 2009 Jun; 113(24):6102-11. PubMed ID: 19366986
[TBL] [Abstract][Full Text] [Related]
17. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2, 3-Dioxgenase Transfected Mesenchymal Stem Cells Induce Kidney Allograft Tolerance by Increasing the Production and Function of Regulatory T Cells.
He Y; Zhou S; Liu H; Shen B; Zhao H; Peng K; Wu X
Transplantation; 2015 Sep; 99(9):1829-38. PubMed ID: 26308414
[TBL] [Abstract][Full Text] [Related]
19. Blockage of indoleamine 2,3-dioxygenase regulates Japanese encephalitis via enhancement of type I/II IFN innate and adaptive T-cell responses.
Kim SB; Choi JY; Uyangaa E; Patil AM; Hossain FM; Hur J; Park SY; Lee JH; Kim K; Eo SK
J Neuroinflammation; 2016 Apr; 13(1):79. PubMed ID: 27090635
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
